ArticleScientific reports2025
Associations of cardiac biomarkers with chronic kidney disease and mortality in US individuals without prevalent cardiovascular disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cardiac Biomarkers in Chronic Kidney Disease: Signal or Noise?Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- Advances in Diagnosis and Treatment of Acute and Chronic Heart Failure: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Ten Hot Topics in Cardiovascular Risk Management for Chronic Kidney Disease.Cardiorenal medicine · 2026Review
- Enhancing cardiac disease detection via a fusion of machine learning and medical imaging.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Our study aims to evaluate the prevalence of elevated cardiac biomarkers, as well as their associations with chronic kidney disease (CKD) and long-term risk of mortality (all-cause and cardiovascular) in the US individuals without known cardiovascular disease. The study population was derived from individuals aged ≥ 20 years in NHANES 1999 to 2004. We calculated the prevalence of elevated cardiac biomarkers in both CKD and non-CKD populations and used multivariable logistic regression to assess the relationships between each cardiac biomarker and CKD. We also used multivariable Cox proportional hazards models and competing risk models to evaluate the adjusted associations between elevated cardiac biomarkers and all-cause and cardiovascular mortality. The crude prevalence of CKD in the overall population was 14.71%. Among CKD individuals, the age-standardized prevalence of elevated NT-ProBNP (≥ 125 pg/mL), hs-cTnT (≥ 6 ng/L), and hs-cTnI (M ≥ 6 ng/L and F ≥ 4 ng/L) were 26.43%, 47.44%, and 19.23%, respectively. After adjusting for cardiovascular and renal risk factors, significant correlations were observed between elevated cardiac biomarkers with CKD. Analysis of follow-up data revealed elevated cardiac biomarkers were independently associated with cumulative occurrence of all-cause mortality (CKD: adjusted hazard ratio [HR]: NT-proBNP: 2.00 [95% CI, 1.56-2.56]; hs-cTnT: 2.89 [95% CI, 1.96-4.26]; hs-cTnI: 1.92 [95% CI, 1.50-2.44]) and cardiovascular mortality (CKD: adjusted hazard ratio [HR]: NT-proBNP: 2.38 [95% CI, 1.61-3.51]; hs-cTnT: 2.70 [95% CI, 1.35-5.40]; hs-cTnI: 2.11 [95% CI, 1.46-3.04]). Additionally, different detection methodologies (Abbott, Siemens, Ortho) do not significantly affect the correlation between hs-cTnI and CKD, with a consistent positive correlation observed. Our research evaluated the substantial burden of elevated cardiac biomarkers in CKD individuals and provided crucial prognostic information regarding the long-term risk of mortality. These findings will offer significant guidance for risk stratification and the formulation of tailored prevention strategies across diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.